Plain-English translation of NCT05796375 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether simple urine tests can replace invasive camera procedures (cystoscopy) for monitoring early-stage bladder cancer. Researchers want to see if two different urine tests—called Xpert and EpiCheck—can safely detect cancer recurrence while reducing the need for uncomfortable procedures. You would be randomly assigned to one of three groups: frequent camera exams, urine testing with the Xpert test, or urine testing with the EpiCheck test.
Currently, people with early-stage bladder cancer need repeated camera procedures to check for cancer coming back, which can be uncomfortable and disruptive to daily life. This trial aims to find out if urine tests can do the same job without the invasiveness, improving quality of life for patients.
You likely qualify if…
You likely don't qualify if…
You will visit the clinic at months 6, 12, 18, and 24 over two years. Depending on which group you're assigned to, you'll either have camera exams at all four visits, or urine tests at months 6 and 18 with camera exams at months 12 and 24. Each visit includes a check-up with your doctor and takes about 1–2 hours. The study measures how these different approaches affect your quality of life.
AI-generated summary from trial data · Jun 7, 2026 · Not medical advice
United States